ALSO NOTED: Voyager ends Phase III early; Allegra cleared for use in children; and much more...

> DURECT announced that Voyager Pharmaceutical had told the company that it was ending a Phase III trial of Memryte for Alzheimer's disease in order to get a possibly earlier look at efficacy data. Memryte uses DURECT's DURIN technology to provide sustained release of the peptide leuprolide acetate and is based on Voyager's patented method of treatment of Alzheimer's disease. Release

> Sanofi-aventis' allergy drug Allegra has been cleared for use in children as young as two. Report

> J&J has gained FDA approval for another indication for Remicade. Report

> Vical is selling $25 million in stock to Singapore-based Temasek Holding. Report

> SIGA Technologies has arranged for a $9 million private placement. Report

And Finally... Buoyed by the response to its new $4 generic drug program, Wal-Mart is accelerating plans to roll it out around the country. Article

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.